CONFIDENCE试验:CKD合并2型糖尿病中年龄与性别的白蛋白尿变化差异
CONFIDENCE试验评估非奈利酮联合恩格列净治疗CKD合并T2D患者,按年龄四分位和性别分层分析UACR变化。结果显示年龄每增加10岁,第180天UACR额外降低10.2%(95%CI -15.5~-4.6),女性较男性多降低18.6%(95%CI 6.3~29.2),联合治疗获益不受年龄和性别影响。
要点
- 年龄每增加10岁,第180天UACR额外降低10.2%,女性较男性多降18.6%。
- 联合治疗获益独立于年龄和性别,交互作用不显著。
- 安全结局在各年龄和性别亚组中一致。
核心结论
- 非奈利酮和恩格列净的降UACR效应随年龄线性增加(每十年约10%),女性降幅比男性多约20%。
- 联合治疗获益独立于年龄和性别。
研究设计与样本
- CONFIDENCE试验(NCT05254002),T2D合并CKD(eGFR 30-90 ml/min/1.73 m2)且UACR 100至<5000 mg/g、稳定使用RAS抑制剂的参与者随机1:1:1接受恩格列净10 mg/日、非奈利酮10或20 mg/日或两者联合。
- 按年龄四分位(≤60岁、61-68岁、69-74岁、>74岁)和性别分层分析。
主要发现
- 年龄增长与基线动脉粥样硬化性心血管疾病患病率更高和eGFR更低相关。
- 第180天UACR变化:年龄每增加10岁额外降低10.2%(95%CI -15.5~-4.6,年龄效应P=0.001)。
- 女性第180天UACR降幅比男性多18.6%(95%CI 6.3~29.2,性别效应P=0.008)。
- 年龄(交互P=0.28)和性别(交互P=0.46)不影响联合治疗效应。
- 安全结局在所有人口学亚组中一致。
关键数值与推荐
- UACR降幅随年龄每十年约10%线性增加。
- 女性UACR降幅比男性多约20%。
临床怎么用
- 临床中可预期老年和女性CKD合并T2D患者使用非奈利酮联合恩格列净降UACR幅度更大。
- 联合治疗决策无需因年龄或性别调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Concurrent initiation of finerenone and empagliflozin can lower albuminuria more than component therapies at Day 180 in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D ). We evaluated baseline clinical characteristics and longitudinal changes in urinary albumin-to-creatinine ratio (UACR) across age and sex cohorts. METHODS: In CONFIDENCE (NCT05254002), participants with T2D, CKD (estimated glomerular filtration rate [eGFR] 30-90 ml/min/1.73 m2), and albuminuria (UACR 100 to <5000 mg/g) on stable doses of renin-angiotensin system inhibitors were randomized 1:1:1 to empagliflozin 10 mg/day, finerenone 10 or 20 mg/day, or both. We stratified participants by age quartiles (≤60 years, 61-68 years, 69-74 years , >74 years) and sex. Outcomes included % change in UACR from baseline over time and incidences of key adverse events. RESULTS: Increasing age was associated with higher baseline prevalence of atherosclerotic cardiovascular disease and lower eGFR. Older age was a significant predictor of UACR reduction, with -10.2% (95% CI: -15.5, -4.6) incremental change per 10-year age increase at Day 180 (P for age effect = 0.001). Women exhibited an 18.6% (95% CI: 6.3, 29.2) greater UACR reduction at Day 180 than men (P for sex effect = 0.008). These effects were independent of treatment; there was no interaction between age (P-interaction = 0.28) or sex (P-interaction = 0.46) on combination therapy treatment effect. Safety outcomes were consistent across all demographics. CONCLUSIONS: The UACR-lowering response of finerenone and empagliflozin scaled linearly with age (10% per decade) and sex (∼20% more among women). The benefit of combination therapy was independent of age and sex.
引用
- Agarwal R, Green JB, Heerspink HJL, et al. Sexual dimorphism and age effects in CKD and type 2 diabetes in the CONFIDENCE trial. Nephrol Dial Transplant. 2026. PMID: 41894225. doi:10.1093/ndt/gfag075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。